pamidronate has been researched along with Leishmaniasis, Visceral in 1 studies
Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ribeiro, JM | 1 |
| Rodrigues-Alves, ML | 1 |
| Oliveira, E | 1 |
| Guimarães, PPG | 1 |
| Maria Murta Santi, A | 1 |
| Teixeira-Carvalho, A | 1 |
| Murta, SMF | 1 |
| Peruhype-Magalhães, V | 1 |
| Souza-Fagundes, EM | 1 |
1 other study available for pamidronate and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Pamidronate, a promising repositioning drug to treat leishmaniasis, displays antileishmanial and immunomodulatory potential.
Topics: Animals; Antiprotozoal Agents; Drug Repositioning; Humans; Interleukin-10; Leishmania infantum; Leis | 2022 |